Cerebellar atrophy in a child with valproate toxicity

Area of Science:

• Neurology
• Pharmacology
• Pediatrics

Background:

• Epilepsy treatment necessitates personalized antiepileptic drug (AED) selection based on patient needs and drug profiles.
• AED choice may require modification due to adverse side effects, impacting treatment efficacy and patient safety.

Observation:

• A 10-year-old patient diagnosed with Lennox Gastaut syndrome experienced seizure recurrence.
• The patient developed hyperammonemic encephalopathy and cerebellar atrophy while undergoing valproate therapy.

Findings:

• Discontinuation of valproate and initiation of lamotrigine led to effective seizure control.
• Cerebellar atrophy is identified as a rare but serious adverse effect associated with valproate treatment.

Implications:

• This case highlights the importance of monitoring for rare but severe adverse effects of AEDs.
• Alternative AEDs like lamotrigine may offer a safer and more effective treatment option for specific epilepsy syndromes.
• Clinicians should consider valproate's potential for causing cerebellar atrophy, especially in pediatric patients.